| $350M | ||
| $241M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $23,401 | 1 | 7 |
Sells | $33,075 | 13 | 93 |
| Reid Laurence | director | 1 | $23,401 | 0 | $0 | $23,401 |
| Wein Matthew | See Remarks | 0 | $0 | 4 | $2,263 | $-2,263 |
| Thomas Brian C. | director | 0 | $0 | 1 | $6,786 | $-6,786 |
| Wapnick Pamela | Chief Financial Officer | 0 | $0 | 4 | $11,282 | $-11,282 |
| Irish Jian | Chief Executive Officer | 0 | $0 | 4 | $12,743 | $-12,743 |
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
Over the last 12 months, insiders at Metagenomi, Inc. Common Stock have bought $23,401 and sold $33,075 worth of Metagenomi, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Metagenomi, Inc. Common Stock have bought $23,401 and sold $43,203 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Reid Laurence (director) — $23,401.
The last purchase of 20,000 shares for transaction amount of $23,401 was made by Reid Laurence (director) on 2026‑09‑09.
| 2026-09-09 | Reid Laurence | director | 20,000 0.0541% | $1.17 | $23,401 | -20.23% | ||
| 2026-09-08 | Sale | Irish Jian | See Remarks | 2,140 0.0057% | $1.16 | $2,479 | -18.02% | |
| 2026-09-08 | Sale | Wapnick Pamela | Chief Financial Officer | 1,911 0.0051% | $1.16 | $2,214 | -18.02% | |
| 2026-09-08 | Sale | Wein Matthew | See Remarks | 358 0.0009% | $1.16 | $415 | -18.02% | |
| 2026-06-05 | Sale | Irish Jian | See Remarks | 3,737 0.0101% | $1.30 | $4,854 | -7.42% | |
| 2026-06-05 | Sale | Wapnick Pamela | Chief Financial Officer | 2,884 0.0078% | $1.30 | $3,746 | -7.42% | |
| 2026-06-05 | Sale | Wein Matthew | See Remarks | 558 0.0015% | $1.30 | $725 | -7.42% | |
| 2026-03-05 | Sale | Irish Jian | Chief Executive Officer | 1,607 0.0043% | $1.60 | $2,571 | -23.60% | |
| 2026-03-05 | Sale | Wapnick Pamela | Chief Financial Officer | 1,581 0.0042% | $1.60 | $2,530 | -23.60% | |
| 2026-03-05 | Sale | Wein Matthew | See Remarks | 482 0.0013% | $1.60 | $771 | -23.60% | |
| 2025-12-05 | Sale | Thomas Brian C. | director | 3,830 0.0103% | $1.77 | $6,786 | -25.84% | |
| 2025-12-05 | Sale | Irish Jian | Chief Executive Officer | 1,602 0.0043% | $1.77 | $2,839 | -25.84% | |
| 2025-12-05 | Sale | Wapnick Pamela | Chief Financial Officer | 1,576 0.0042% | $1.77 | $2,793 | -25.84% | |
| 2025-12-05 | Sale | Wein Matthew | See Remarks | 199 0.0005% | $1.77 | $353 | -25.84% | |
| 2025-09-05 | Sale | Thomas Brian C. | director | 2,701 0.0074% | $1.81 | $4,889 | -22.51% | |
| 2025-09-05 | Sale | Irish Jian | Chief Executive Officer | 1,602 0.0044% | $1.81 | $2,900 | -22.51% | |
| 2025-09-05 | Sale | Wapnick Pamela | Chief Financial Officer | 1,576 0.0043% | $1.81 | $2,853 | -22.51% | |
| 2025-09-05 | Sale | Wein Matthew | See Remarks | 199 0.0005% | $1.81 | $360 | -22.51% | |
| 2025-06-06 | Sale | Thomas Brian C. | Chief Executive Officer | 10,785 0.0286% | $1.75 | $18,874 | -3.47% | |
| 2025-06-06 | Sale | Irish Jian | See Remarks | 6,390 0.0169% | $1.75 | $11,183 | -3.47% |
| Increased Positions | 26 | +35.14% | 2M | +32.02% |
| Decreased Positions | 29 | -39.19% | 829,461 | -13.06% |
| New Positions | 11 | New | 394,110 | New |
| Sold Out Positions | 10 | Sold Out | 419,778 | Sold Out |
| Total Postitions | 71 | -4.05% | 8M | +18.96% |